The state of Texas currently has 52 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
Recruiting
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are: To evaluate the safety of NP-101, as well as establish the maximum tolerated dose in high risk Covid-19 positive patients. Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Clinical Trial Network, Houston, Texas +1 locations
Conditions: COVID-19
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
Recruiting
This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and numb... Read More
Gender:
All
Ages:
Between 6 months and 37 years
Trial Updated:
03/14/2024
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +3 locations
Conditions: COVID-19 Infection, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Strategies and Treatments for Respiratory Infections &; Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of S-217622 when given in addition to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Hendrick Medical Center (Site 080-014), Abilene, Texas +9 locations
Conditions: COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Recruiting
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Atea Study Site, Dallas, Texas +11 locations
Conditions: SARS CoV 2 Infection, COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: DHR Health, Edinburg, Texas +1 locations
Conditions: COVID-19
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
03/12/2024
Locations: Driscoll Children's Hospital, Corpus Christi, Texas +8 locations
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 330 - Clinical Trial Network, Houston, Texas +2 locations
Conditions: COVID-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Hendrick Medical Center (Site 080-014), Abilene, Texas +5 locations
Conditions: COVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Recruiting
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: SARS-CoV Infection, COVID-19
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Baptist Hospitals of Southeast Texas, Beaumont, Texas +1 locations
Conditions: Infectious Pneumonia, Severe COVID-19
Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
Recruiting
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
Recruiting
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Gender:
All
Ages:
17 years and below
Trial Updated:
02/29/2024
Locations: UT Physicians - Pediatric Center - Texas Medical Center, Houston, Texas
Conditions: COVID-19